{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023059","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2026-05-14T20:05:17+00:00","discovered_at":"2026-05-14T20:07:00.245507+00:00","generated_at":"2026-05-14T21:01:58.880211+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones","bullets":["Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.","Net loss $9.1M ($4.06/share) vs $7.5M ($7.05/share); adjusted EBITDA loss $8.7M.","Cash $8.2M at Mar 31, 2026, down from $11.9M at Dec 31, 2025.","Received CDSCO license for CoSara PCR Pro instrument in India; ISO 13485 certification for manufacturing facility.","Completed enrollment in upper respiratory test clinical study with >1,400 patients; advancing TB study in India."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023059","json":"https://secwatch.observer/filing/0001493152-26-023059.json","markdown":"https://secwatch.observer/filing/0001493152-26-023059.md","text":"https://secwatch.observer/filing/0001493152-26-023059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/0001493152-26-023059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:01:58.880211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f22f1c1468c623c2da131d400ad8ed3dc37dc1ed","claim":"Co-Diagnostics, Inc. reported first quarter ended March 31, 2026 results: revenue $0.15 million, net income Net loss of $9.1 million, or $4.06 per share, EPS $4.06 per share.","evidence_excerpt":"global stakeholders ● Expanded the intellectual property portfolio with the issuance of a new international patent in Japan First Quarter 2026 Financial Results: ● Revenue of $0.15 million, compared to $0.05 million in the first quarter of 2025 ● Operating expenses of $9.2 million, compared to $8.6 million in the same period last year, driven by research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/0001493152-26-023059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$0.15 million"},{"label":"Net income","value":"Net loss of $9.1 million, or $4.06 per share"},{"label":"EPS","value":"$4.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}